Cat. No. 0652
Chemical Name: N-(2,6-dioxo-3-piperidinyl)phthalimide
Biological ActivityTeratogen, sedative-hypnotic with inherent anti-inflammatory properties. A selective inhibitor of tumor necrosis factor α (TNF-α) synthesis.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Merck Index 12 9390.
Sampaio et al (1991) Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J.Exp.Med. 173 699. PMID: 1997652.
Makonkawkeyoon et al (1993) Thalidomide inhibits the replication of human-immunodeficiency-virus type 1. Proc.Natl.Acad.Sci.U.S.A. 90 5974. PMID: 8327469.
Kanbayashi et al (1996) Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy. Neuroreport 7 1881. PMID: 8905685.
Boireau et al (1997) Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. Neurosci.Lett. 234 123. PMID: 9364513.
Zhang et al (2008) Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. J.Exp.Clin.Cancer Res. 27 60. PMID: 18983651.
If you know of a relevant citation for this product please let us know.
Keywords: Thalidomide, supplier, TNF-α, TNF-alpha, synthesis, inhibitors, Interleukins, Tumor, Necrosis, Factor-α, Factor-alpha, Cytokines, Signaling, Signalling, teratogen, anti-inflammatory
Find multiple products by catalog number
New Products in this Area
Reported macrophage migration inhibitory factor (MIF) inhibitorSulfasalazine
Inhibitor of NF-κB activation; also inhibits SXC
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.